Valeant Pharma (NYSE: VRX) is on watch following a new article from ProPublica which highlights documents that raise new questions ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Short Sales Trader Talk

SEC Won't Comment on Speculation of Valeant Pharmaceuticals (VRX) ProbeOctober 22, 2015 3:43 PM Valeant Pharma (VRX) to Hold Investor Conference Call on October 26October 22, 2015 2:39 PM Short Valeant Pharma (VRX) but won't discuss his trading - Citron's LeftOctober 22, 2015 12:45 PM Valeant Pharma (VRX) Continues Free Fall; Down 20%October 22, 2015 11:26 AM BMO Capital Downgrades Valeant Pharmaceuticals (VRX) to Market Perform; Cannot Defend the Specialty Pharmacy StructureOctober 22, 2015 7:00 AM Specialty pharmacies in spotlight as Valeant ties questioned October 21, 2015 9:03 PM Citron Research says it has a 'smoking gun' on Valeant Pharma (VRX)October 21, 2015 10:10 AM